Experimental drug roscovitine tested in cystic fibrosis patients
NCT ID NCT02649751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tested an experimental drug called roscovitine in 36 adults with cystic fibrosis who have a common genetic mutation and a chronic lung infection. The goal was to check the safety of different doses given in short cycles. The study was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roscovitine (also called Seliciclib)
What this could lead to
If successful, this could point toward a new treatment to control lung infections in people with cystic fibrosis.
What could go wrong
This is an early, small trial that was terminated, so results are limited. The drug may not prove safe or effective, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Lyon Sud
Lyon, 69495, France
-
CHR - Hôpital Calmette
Lille, 59037, France
-
CHU Nantes
Nantes, 44093, France
-
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, France, 33604, France
-
CHU de Nice - Hôpital Pasteur
Nice, France, 06001, France
-
Centre Hospitalier Bretagne Atlantique
Vannes, France, 56017, France
-
Centre de Perharidy
Roscoff, 29684, France
-
Centre de Ressources et de Compétences de la mucoviscidose
Reims, France, 51100, France
-
Hôpital Arnaud de Villeneuve
Montpellier, 34295, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Larrey
Toulouse, 30030, France